Comparative study of non nucleoside inhibitors with HIV-1 reverse transcriptase based on 3D-QSAR and docking

The intermolecular interaction between two types of non nucleoside reverse transcriptase inhibitors (NNRTIs), HEPT and TIBO, and HIV reverse transcriptase receptor (HIVRT) was investigated. The result of docking study showed that two types of NNRTIs presented similar interaction mechanism with HIVRT. The most active compound of every type of inhibitors could form one hydrogen bond with the residue Lys101 and has hydrophobic interaction with residues Tyr181, Tyr188 and Tyr318, etc. Three 3D-QSAR models including two partial correlation models (one for each family of HEPT and TIBO) and a mixed model gathering two families were constructed. Comparative study of these models indicated that the mixed model offered the strongest prediction ability. For this model, the cross-validated q 2 values were 0.720 and 0.675, non-cross-validated r 2 values were 0.940 and 0.920 for CoMFA and CoMSIA, respectively. It has been validated by using a test set of 27 inhibitors. Compared with previously reported works, our model showed better prediction ability. It could help us to insight the interaction between NNRTIs and HIVRT, and to design new anti-HIV NNRTIs inhibitors.

[1]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[2]  Richard T. Walker,et al.  Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. , 1996, Journal of medicinal chemistry.

[3]  U. Singh,et al.  A NEW FORCE FIELD FOR MOLECULAR MECHANICAL SIMULATION OF NUCLEIC ACIDS AND PROTEINS , 1984 .

[4]  P. Kollman,et al.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.

[5]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[6]  Mehdi Jalali-Heravi,et al.  Use of Artificial Neural Networks in a QSAR Study of Anti-HIV Activity for a Large Group of HEPT Derivatives , 2000, J. Chem. Inf. Comput. Sci..

[7]  Matthew Clark,et al.  The Probability of Chance Correlation Using Partial Least Squares (PLS) , 1993 .

[8]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[9]  Rajni Garg,et al.  Comparative Quantitative Structure—Activity Relationship Studies on Anti-HIV Drugs , 2000 .

[10]  Yvonne Jones,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors , 1995, Nature Structural Biology.

[11]  R T Walker,et al.  Specific anti-HIV-1 "acyclonucleosides" which cannot be phosphorylated: synthesis of some deoxy analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. , 1991, Journal of medicinal chemistry.

[12]  H. Mitsuya,et al.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Jarmo Huuskonen.  QSAR Modeling with the Electrotopological State: TIBO Derivatives , 2001, J. Chem. Inf. Comput. Sci..

[14]  Julian Tirado-Rives,et al.  Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations. , 2002, Journal of medicinal chemistry.

[15]  D W Barry,et al.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J Andrew McCammon,et al.  Studying enzyme binding specificity in acetylcholinesterase using a combined molecular dynamics and multiple docking approach. , 2002, Journal of the American Chemical Society.

[17]  C. Monneret,et al.  A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition. , 1997, Journal of medicinal chemistry.

[18]  G Klebe,et al.  Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.

[19]  A. Leach.  Molecular Modelling: Principles and Applications , 1996 .

[20]  J. Cameron,et al.  The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro , 1992, Antimicrobial Agents and Chemotherapy.

[21]  Erik De Clercq,et al.  Lithiation of Uracilnucleosides and its Application to the Synthesis of a New Class of Anti-HIV-1 Acyclonucleosides , 1991 .

[22]  R. Cramer,et al.  Validation of the general purpose tripos 5.2 force field , 1989 .

[23]  F. Uckun,et al.  Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. , 2000, Biochemical pharmacology.

[24]  P A Kollman,et al.  Prediction of the binding free energies of new TIBO-like HIV-1 reverse transcriptase inhibitors using a combination of PROFEC, PB/SA, CMC/MD, and free energy calculations. , 1999, Journal of medicinal chemistry.

[25]  R T Walker,et al.  A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. , 1989, Journal of medicinal chemistry.

[26]  R T Walker,et al.  Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). , 1991, Journal of medicinal chemistry.

[27]  R T Walker,et al.  Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. , 1989, Biochemical and biophysical research communications.

[28]  D I Stuart,et al.  Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants. , 1999, Journal of medicinal chemistry.

[29]  E. De Clercq,et al.  New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs , 1994, Antimicrobial Agents and Chemotherapy.

[30]  David S. Goodsell,et al.  Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4 , 1996, J. Comput. Aided Mol. Des..

[31]  S Shigeta,et al.  A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). , 1991, Journal of medicinal chemistry.

[32]  E. De Clercq.  HIV‐1‐specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase , 1993, Medicinal research reviews.

[33]  H. Mitsuya,et al.  In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. , 1989, Science.

[34]  J Tirado-Rives,et al.  Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations. , 2001, Journal of medicinal chemistry.

[35]  F. Gago,et al.  Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. , 2001, Journal of medicinal chemistry.

[36]  William L. Jorgensen,et al.  Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Sustiva through Computation of Resistance Profiles , 2000 .

[37]  C. Hansch,et al.  Comparative Quantitative Structure−Activity Relationship Studies on Anti-HIV Drugs , 1999 .

[38]  R. T. Walker,et al.  Synthesis and Anti‐HIV Activity of 2‐, 3‐, and 4‐Substituted Analogues of 1‐((2‐Hydroxyethoxy)methyl)‐6‐(phenylthio)thymine (HEPT). , 1991 .

[39]  A Tropsha,et al.  Cross-validated R2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results. , 1995, Journal of medicinal chemistry.